NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Capital World Investors

Capital World Investors boosted its stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 1.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,984,000 shares of the company’s stock after purchasing an additional 161,289 shares during the quarter. Capital World Investors owned approximately 0.09% of NewAmsterdam Pharma worth $350,239,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its position in NewAmsterdam Pharma by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock valued at $114,332,000 after purchasing an additional 697,129 shares during the period. Adage Capital Partners GP L.L.C. boosted its position in NewAmsterdam Pharma by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after purchasing an additional 1,062,359 shares during the period. Polar Capital Holdings Plc boosted its position in NewAmsterdam Pharma by 15.6% during the 3rd quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock valued at $82,807,000 after purchasing an additional 393,855 shares during the period. Alliancebernstein L.P. boosted its position in NewAmsterdam Pharma by 4.0% during the 2nd quarter. Alliancebernstein L.P. now owns 2,331,583 shares of the company’s stock valued at $42,225,000 after purchasing an additional 89,630 shares during the period. Finally, Duquesne Family Office LLC boosted its position in NewAmsterdam Pharma by 131.2% during the 3rd quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after purchasing an additional 1,091,525 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 65,000 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total value of $2,319,850.00. Following the transaction, the chief accounting officer owned 24,353 shares in the company, valued at $869,158.57. The trade was a 72.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Louis G. Lange sold 44,619 shares of the business’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $30.42, for a total value of $1,357,309.98. Following the completion of the transaction, the director owned 10,360 shares in the company, valued at $315,151.20. This trade represents a 81.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 12.74% of the company’s stock.

Analyst Upgrades and Downgrades

NAMS has been the subject of several recent analyst reports. HC Wainwright upgraded shares of NewAmsterdam Pharma to a “strong-buy” rating in a report on Thursday, February 19th. Truist Financial started coverage on shares of NewAmsterdam Pharma in a report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 target price for the company. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $48.60.

NewAmsterdam Pharma Trading Down 1.8%

Shares of NAMS stock opened at $30.95 on Tuesday. NewAmsterdam Pharma Company N.V. has a 1-year low of $17.63 and a 1-year high of $42.21. The company has a market capitalization of $3.62 billion, a price-to-earnings ratio of -17.29 and a beta of 0.07. The stock’s fifty day simple moving average is $33.52 and its 200-day simple moving average is $33.88.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The business had revenue of $3.04 million for the quarter. On average, sell-side analysts predict that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current year.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.